REG - Physiomics PLC - Appointment of Stewart Williams as Consultant

PhysiomicsAnnouncement

12/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260512:nRSL8735Da&default-theme=true

RNS Number : 8735D  Physiomics PLC  12 May 2026

12 May 2026

 

Physiomics plc

 

("Physiomics" or the "Company")

 

Appointment of Stewart Williams as Consultant

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce the appointment of
Stewart Williams FCILT as a consultant to the Company.

 

Mr Williams will support the Board and management team during the Company's
senior leadership transition, providing strategic, operational and programme
delivery expertise to assist with the ongoing development and execution of the
Company's growth strategy.

 

Mr Williams brings more than 30 years of experience advising and leading
complex transformation programmes across life sciences and other regulated
sectors. His background includes senior consulting roles with PwC and KPMG,
alongside leadership positions delivering large-scale operational and digital
transformation programmes for organisations including AstraZeneca, Victrex,
BAE Systems and Co-operative Financial Services. He currently serves as Head
of Planning for AstraZeneca's c. $2 billion AXIAL transformation programme.

 

The Board believes Stewart's extensive expertise in governance, operational
delivery, programme management and strategic execution will provide valuable
support as Physiomics continues to advance its commercial and operational
objectives.

 

The Company continues to see steady levels of commercial activity across both
new and existing client relationships, including a combination of contract
awards and ongoing programme renewals. This reflects the Board's expectations
for continued operational progress and supports the Company's broader strategy
of building long-term, recurring client engagements.

 

Stewart Williams commented: "I am pleased to be working with Physiomics and
the new Board at an important stage in the Company's development. Physiomics
has built strong scientific and technical capabilities, and I look forward to
supporting the leadership team through this transition period. My focus will
be on helping the Company execute efficiently, strengthen operational delivery
and, where possible, help expedite key projects and strategic initiatives."

 

Executive Director Mike Whitlow commented: "We are delighted to welcome
Stewart to Physiomics. His depth of experience across transformation
leadership, governance and operational delivery within highly regulated
environments will be of considerable value to the Company as we continue to
strengthen the business and execute on our strategic priorities."

 

ENDS

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 Physiomics plc                    Email:  info@physiomics.co.uk

 Mike Whitlow

 Strand Hanson Ltd (NOMAD)         Tel:  +44 (0)20 7409 3494

 James Dance & James Bellman

 Hybridan LLP (Broker)             Tel:  +44 (0) 203 764 2341

 Claire Louise Noyce

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting- edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 140 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEANSFFFEKEFA



            Copyright 2019 Regulatory News Service, all rights reserved